Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratect (BT681) in primary immunodeficiency disease
2004-004465-15Phase 3Completed
- Sponsor
- Biotest AG
- Start
- Feb 2005
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of IgPro10 in Immunogenetic disorder, agammaglobulinemia, hypogammaglobulinemia and 3 more, sponsored by Biotest AG. Primary endpoint: Number of acute serious bacterial infections per subject per year. Started Feb 2005; status: completed.
02
Drugs
IgPro10
03
Conditions
Immunogenetic disorderagammaglobulinemiahypogammaglobulinemiacommon variable immunodeficiency (CVID)severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on 2004-004465-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004465-15.